Generation of the induced human pluripotent stem cell lines CSSi009-A from a patient with a GNB5 pathogenic variant, and CSSi010-A from a CRISPR/Cas9 engineered GNB5 knock-out human cell line by N. Malerba et al.
Contents lists available at ScienceDirect
Stem Cell Research
journal homepage: www.elsevier.com/locate/scr
Lab Resource: Multiple Cell Lines
Generation of the induced human pluripotent stem cell lines CSSi009-A from
a patient with a GNB5 pathogenic variant, and CSSi010-A from a CRISPR/
Cas9 engineered GNB5 knock-out human cell line
Natascia Malerbaa, Patrizia Benzonib, Gabriella Maria Squeoa, Raffaella Milanesib,
Federica Giannettib, Lynette G. Sadleirc, Gemma Pokec, Bartolomeo Augelloa, Anna Irma Crocea,
Andrea Barbutib, Giuseppe Merlaa,⁎
a Division of Medical Genetics, Fondazione IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy
b The PaceLab, Department of Biosciences, Università degli Studi di Milano, Italy
c Department of Paediatrics and Child Health, University of Otago Wellington, Wellington, New Zealand
A B S T R A C T
GNB5 loss-of-function pathogenic variants cause IDDCA, a rare autosomal recessive human genetic disease characterized by infantile onset of intellectual disability,
sinus bradycardia, hypotonia, visual abnormalities, and epilepsy. We generated human induced pluripotent stem cells (hiPSCs) from skin fibroblasts of a patient with
the homozygous c.136delG frameshift variant, and a GNB5 knock-out (KO) line by CRISPR/Cas9 editing. hiPSCs express common pluripotency markers and dif-
ferentiate into the three germ layers. These lines represent a powerful cellular model to study the molecular basis of GNB5-related disorders as well as offer an in vitro
model for drug screening.
Resource utility
hiPSC lines offer the opportunity to produce large amount of pa-
tient-specific and GNB5 knock-out cells, and to differentiate them into
cell types relevant to the GNB5 disorders, like cardiomyocytes and
neurons. Their characterization will give insights on the disorder pa-
thogenesis and offer a powerful in vitro model for drug screening.
Resource details
Bi-allelic non-sense and frameshift mutations in the GNB5 gene,
encoding the β5 subunit of heterotrimeric G-proteins (Gβ5), are asso-
ciated with the autosomal-recessive multisystem syndrome named
Intellectual Developmental Disorder with Cardiac Arrhythmia (IDDCA;
MIM#617173) (Lodder et al., 2016). This syndrome is characterized by
intellectual disability, developmental and epileptic encephalopathy,
retinal abnormalities and early-onset sinus node dysfunction (with
bradycardia). Bi-allelic GNB5 missense variants correlate with a milder
manifestation of the disorder, characterized by language delay, atten-
tion-deficit/hyperactivity disorder, and mild cognitive impairment with
or without cardiac arrhythmia (LADCI; MIM#617182) (Shamseldin
et al., 2016). The biological mechanisms underlying this syndrome are
unclear. In order to elucidate how loss of Gβ5 activity affects functional
properties of excitable cells involved in the syndrome, such as cardio-
myocytes and neurons, the availability of an unlimited source of these
fully differentiated cell types is a major requirement.
Here we report the generation of: (i) a hiPSC line from a 10-years-
old male proband carrying the c.136delG (p.E46fs8X) homozygous
frameshift GNB5 mutation and (ii) an hiPSC line, from a healthy donor,
in which we selectively knocked-out (KO) GNB5.
hiPSCs were generated from skin fibroblasts by the mRNA-based
reprogramming method to generate integration free, virus-free hiPSCs,
using a single transfection step (Simplicon™ RNA Reprogramming Kit;
Merck-Millipore). The first colonies appeared 10 days after transfection
and displayed the classical pluripotent stem cell morphology
(Supplementary Fig. 1A). The hiPSC control line was handled for
genome editing by CRISPR/Cas9; a clone with the homozygous GNB5
frameshift variant c.204_208delCATGG was selected and amplified
(Table 1).
The expression of pluripotency genes (NANOG, OCT4, LIN28, REX1,
SOX2, and GAPDH as reference gene), assessed by RT-qPCR, was higher
in both the hiPSC lines than in the fibroblast of origin (Fig. 1A). Protein
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expression of NANOG, OCT4, SOX2 and TRA-1-60 was also assessed by
Immunocytochemistry (Fig. 1B). Moreover, quantitative flow cytometry
analysis revealed that between 85.3 %and 99.4% of the cells of both
hiPSC lines expressed the pluripotency markers SOX2 and SSEA-4
(Fig. 1C).
We then confirmed that both hiPSC lines were able to generate cells
belonging to the three germ layers, as demonstrated by the positive
expression of mesodermal (CD31, SMA), endodermal (SOX7, AFP), and
ectodermal (KTR14, NCAM1) markers (Fig. 1D), achieved by RT-qPCR
using β-actin as reference gene to normalize the expression of differ-
entiation markers. The hiPSC lines showed a normal karyotype (Sup-
plementary Fig. 1B) and presented the expected mutations in GNB5
gene (Fig. 1E). Genetic DNA fingerprinting was performed for both
hiPSC lines and their fibroblast counterparts, confirming their genetic
identity (Table 2). All hiPSC lines were negative for mycoplasma con-
tamination (Supplementary Fig. 1C).
Materials and methods
Cell culture and reprogramming
Skin biopsies from an IDDCA patient and a healthy individual were
used to establish primary dermal fibroblast cultures. For primary fi-
broblasts reprogramming, the Oct4, Klf4, Sox2, and Glis1 transgenes
were expressed by Simplicon™ RNA Reprogramming Kit (Merck-
Millipore), following the manufacturer's instructions. On day 28, in-
dividual hiPSC colonies were picked and growth on Matrigel™
(Corning) in TeSR-E8 medium and propagated using ReLeSR (Stem Cell
Technologies) medium at 37 °C and 5% CO2.
Generation of hiPSC GNB5 Knock-out through CRISPR/Cas9
Healthy control hiPSCs were transiently transfected with 2 μg of
Gβ5 CRISPR/Cas9 KO Plasmids (Santa Cruz). After 48 h, GFP positive
transfected cells were enriched by FACS analysis and dispersed at low
density into Matrigel-coated 10 cm2 dishes in TeSR-E8 Medium con-
taining 5 μM ROCK inhibitor. After approximately 20 days, largest co-
lonies were picked and expanded. Each clone was analysed for the
GNB5 variants by Sanger Sequencing. A positive clone was selected and
further analysed.
Mycoplasma test
Mycoplasma contamination was ruled out by PCR using primers
able to recognize most of the Mycoplasma species (Supplementary
Fig. 1C). The 500 bp PCR product size was carried out by iCycler (Bio-
Rad, USA) using the following PCR steps: 1. Denaturation at 95 °C for
5min; 2. Denaturation at 95 °C for 30 s; 3. Primer annealing at 38 °C for
30 s; 4. Primer extension at 72 °C for 1min; 5. Primer extension at 72 °C
for 10min. Steps 2 to 4 was repeated 35 times.
Karyotype analysis
Cytogenetic G-banding analysis was performed on indicated cells
(Supplementary Fig. 1B) at passage number 12, as previously described
(Drets and Shaw, 1971). Twenty metaphases were counted and three
karyotypes were visualized with a 1000× objective (Zeiss, Germany)
and analysed by G-banding at GAG 300–400 band resolution on
average, using Applied Imaging Cito-Vision (Version 7.5).
Genotyping, sequencing, and STR analysis
Genomic DNA was extracted using Allprep DNA/RNA Mini kit
(Qiagen) and GNB5 confirmed by Sanger sequencing (Fig. 1E; Table 3).
For STR analysis, we used the Promega PowerPlex 16 PCR kit (Pro-
mega, USA) that analysed 16 loci (Table 2).
RNA isolation and quantitative RT-PCR (RT-qPCR)
Total RNA was extracted using RNeasy Mini Kit (Qiagen, Germany).
QuantiTect Reverse Transcription Kit (Qiagen) was used to carry out
cDNA synthesis. cDNA was amplified using Power SYBR Green PCR
Master Mix (Applied biosystem) on ABI PRISM 7009HT System
(Table 3).
Immunofluorescence staining
The hiPSCs were fixed in 4% paraformaldehyde for 15min at room
temperature (RT). Fixed cells were permeabilized and blocked for
30min at RT with PBS containing 10% donkey serum (Jackson
ImmunoResearch) and 0.1% TritonX-100 (VWR). Cells were then in-
cubated with primary antibodies for 2 h at RT in 10% donkey serum in
PBS. The secondary antibodies were thereafter added for 1 h at RT in
the dark, followed by nuclei counterstain with DAPI. Images were ac-
quired on an Inverted Fluorescence Microscope (Axiovert 200M, Zeiss
Carl; Software: AxioVision release 4.7.2 Dec 2008).
Flow cytometry
Flow Cytometry analysis was performed using Multi-Color Flow
Cytometry Kit (R&D System) following manufacturer's instruction.
Samples were analysed using FACSAria™ flow cytometry (BD
Biosciences).
In vitro differentiation by embryoid body (EB) formation
Embryoid bodies (EBs) were formed from iPSCs detached and grown
in ultra-low attachment plates (Corning) for 7 days in DMEM-F12 with
20% fetal bovine serum, 1mM NEAAs, 2mM L-Glutamine, 1% peni-
cillin-Streptomycin and 0.1mM β-mercaptoethanol. EBs were then
seeded onto 0.1% gelatin-coated dishes for further 10 days of differ-
entiation and analysed by RT-qPCR for endodermal, mesodermal, and
ectodermal genes.
Table 1
Summary of lines.
iPSC line names Abbreviation in figures Gender Age Ethnicity Genotype of locus Disease
CSSi009-A Male 10 Asian Hom c.136delG IDDCA
CSSi010-A Female 48 Caucasian Hom c.204_208delCATGG Induced homozygous GNB5 gene Knock-out
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Fig. 1. Characterization of CSSi009-A and CSSi010-A lines.
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Table 2
Characterization and validation.
Classification Test Result Data
Morphology Phase contrast bright field microscopy Normal morphology Supplementary Fig. 1A
Phenotype Quantitative analysis by RT-qPCR Expression of high levels of the pluripotency markers: OCT4, SOX2, NANOG,
LIN28 and REX1. Reference genes: βactin and GAPDH
Fig. 1 panel A
Qualitative analysis by
Immunocytochemistry
Both hiPSC lines expressed the pluripotency markers: OCT4, SOX2, NANOG,
TRA-1-60
Fig. 1 panel B
Flow cytometry CSSi009-A showed positivity to: SSEA4 99.4 ± 0.05%;
SOX2=85.3 ± 0.90%; CSSi010-A showed positivity to: SSEA4
96.9% ± 0.15%; SOX2 95% ± 0.56%
Fig. 1 panel C
Genotype Karyotype (G-banding) and resolution Normal karyotype 46XY GDB1307_Z2#1 (CSSi009-A); Normal karyotype
46XX GNB5_KO#5A (CSSi010-A); Resolution 300–400 bands
Supplementary Fig. 1B
Identity Microsatellite PCR (mPCR) Not performed
STR analysis The STR profiles of both cell lines matched with that of the parental
fibroblast cells. 16 loci analysed: Amelogenin (for gender identification),
D3S1358, TH01, D21S11, D18S51, Penta_E, D5S818, D13S317, D7S820,
D16S539, CSF1PO, Penta_D, Vwa, D8S1179, TPOX and FGA (Promega
PowerPlex 16 kit)
Submitted in archive with
journal
Mutation analysis (if
applicable)
Sanger Sequencing c.136delG (CSSi009-A); c.204_208delCATGG (CSSi010-A) Fig. 1 panel E
Southern Blot OR WGS Not performed Not performed
Microbiology and
virology
Mycoplasma Mycoplasma testing by RT-PCR: Negative Supplementary Fig. 1C
Differentiation potential Spontaneous differentiation through
Embryoid body (EB) formation
All cell lines expressed genes of the three germ layers when subjected to
spontaneous differentiation in EBs. (SOX7 and AFP for endoderm; CD31,
SMA for mesoderm; KRT14 and NCAM1 for ectoderm)
Fig. 1 panel D
Donor screening
(Optional)
HIV 1+2 Hepatitis B, Hepatitis C N/A N/A
Genotype additional info
(Optional)
Blood group genotyping N/A N/A
HLA tissue typing N/A N/A
Table 3
Reagents details.
Antibodies used for immunocytochemistry/flow-citometry
Antibody Dilution Company Cat # and RRID
Pluripotency markers (Immunocytochemistry) Mouse anti-OCT4 1:100 Santa Cruz Biotech; Cat# sc-5279; RRID:AB_628051
Rabbit anti-SOX2 1:500 Abcam; Cat# ab97959; RRID:AB_2341193
Goat anti-NANOG 1:100 Everest Biotech; Cat# EB06860; RRID:AB_2150379
StainAlive TRA-1-60 (DyLight™488) 1:200 Stemgent; Cat# 09-0068; RRID:AB_2233143
Pluripotency markers (flow cytometry) PE-SOX2 Mouse IgG2A 1:20 R&D System; Cat# IC2018P; RRID:AB_357273
CFS- SSEA-4 Mouse IgG3 1:20 R&D System; Cat# FAB1435F; RRID:AB_952015
PE Isotype control- mouse IgG2A 1:20 R&D System; Cat# IC003P; RRID:AB_357245
CFS Isotype control- Mouse IgG3 1:20 R&D System; Cat# IC007F; RRID:AB_952037
Differentiation markers N/A N/A
Secondary antibodies (Immunocytochemistry) Alexa Fluor®568 Goat Anti-Mouse 1:400 Thermo Fisher Scientific; Cat#A11004, RRID AB_2534072
Alexa Fluor®488 Goat Anti-Rabbit 1:400 Thermo Fisher Scientific; Cat#A11008, RRID AB_143165
Alexa Fluor®488 Donkey Anti-Goat 1:400 Thermo Fisher Scientific; Cat#A11055, RRID AB_2534102
Primers
Target Forward/Reverse primer (5′-3′)
Pluripotency markers (RTqPCR) OCT4 CGACCATCTGCCGCTTTG/GCCGCAGCTTACACATGTTCT
Pluripotency markers (RT-qPCR) SOX2 CGCGATGCCGACAAGAA/AAAAATAGTCCCCCAAAAAGAAGTC
Pluripotency markers (RT-qPCR) NANOG AAATCTAAGAGGTGGCAGAAAAACA/CTTCTGCGTCACACCATTGC
Pluripotency markers (RT-qPCR) LIN28 CCGGACCTGGTGGAGTATTCT/CGCTTCTGCATGCTCTTTCC
Pluripotency markers (RT-qPCR) REX1 CCTGCAGGCGGAAATAGAAC/GCACACATAGCCATCACATAAGG
Three germ layer markers (endoderm) (RT-qPCR) SOX7 TGAACGCCTTCATGGTTTG/AGCGCCTTCCACGACTTT
Three germ layer markers (endoderm) (RT-qPCR) AFP GTGCCAAGCTCAGGGTGTAG/CAGCCTCAAGTTGTTCCTCTG
Three germ layer markers (mesoderm) (RT-qPCR) CD31 ATGCCGTGGAAAGCAGATAC/CTGTTCTTCTCGGAACATGGA
Three germ layer markers (mesoderm) (RT-qPCR) SMA GTGATCACCATCGGAAATGAA/TCATGATGCTGTTGTAGGTGGT
Three germ layer markers (ectoderm) (RT-qPCR) KRIT14 CACCTCTCCTCCTCCCAGTT/ATGACCTTGGTGCGGATTT
Three germ layer markers (ectoderm) (RT-qPCR) NCAM1 CAGATGGGAGAGGATGGAAA/CAGACGGGAGCCTGATCTCT
House-keeping genes (RT-qPCR) GAPDH GAAGGTGAAGGTCGGAGTC/GAAGATGGTGATGGGATTTC
ACTB CACTCTTCCAGCCTTCCTTC/AGTGATCTCCTTCTGCATCCT
Genotyping
Targeted mutation analysis (Sequencing) GNB5 TGTGGCTTGTTATGGAGGAA/ACCCGCTCACCTGTTATGC
Mycoplasma detection TGCACCATCTGTCATTCTGTTAACCTC/ACTCCTACGGGAGGCAGCAGTA
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Key resources table
Unique stem cell lines
identifier
CSSi009-A
CSSi010-A
Alternative names of st-
em cell lines
GDB1307_Z2#1 (CSSi009-A)
GNB5_KO#5A (CSSi010-A)
Institution Division of Medical Genetics, Fondazione IRCCS Casa
Sollievo della Sofferenza, Italy
Contact information of
distributor
Giuseppe Merla g.merla@operapadrepio.it
Type of cell lines hiPSC
Origin Human
Cell Source Skin fibroblasts
Clonality Clonal
Method of reprogram-
ming
mRNA-based reprogramming method
Multiline rationale Generate hiPSC from IDDCA patient with GNB5 mutation
(hereditary homozygous variant c.136delG) along with
hiPSC cell line GNB5 knock-out (homozygous variant
c.204_208delCATGG)
Gene modification Yes
Type of modification Induced homozygous GNB5 gene Knock-out
Associated disease Intellectual Development Disorder with Cardiac
Arrhythmia (IDDCA; MIM#617173)
Gene/locus G Protein Subunit Beta 5-GNB5/chromosome 15q21.2
Method of modification Gβ5 CRISPR/Cas9 KO Plasmid
Name of transgene or r-
esistance
GFP
Inducible/constitutive
system
N/A
Date archived/stock da-
te
November 2018 (CSSi009-A)
June 2018 (CSSi010-A)
Cell line repository/ba-
nk
Genomic and Genetic Disorders Biobank (GGDB) (http://
biobanknetwork.telethon.it/)
Ethical approval Fibroblasts were obtained from skin biopsies of a patient
and of a healthy control after signing the appropriate
informed consent, provided by Genomic and Genetic
Disorders Biobank, member of the Telethon Network of
Genetic Biobanks. The generation and use of hiPSCs was
reviewed and approved by Ethical Committee at
Fondazione IRCCS Casa Sollievo della Sofferenza (14/11/
2018, 156/CE)
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.scr.2019.101547.
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